News, media & research

Microfluidic technology may offer faster and more controlled ways to produce radiotracers for medical imaging, including studies into Parkinson’s disease, thanks to a first of its kind approach in the Southern Hemisphere at ANSTO.

Ever wondered what it would be like to stand face-to-face with a group of Nobel Prize winners and share your ground-breaking work? ANSTO's Anwen Krause-Heuer was fortunate enough and reported on her trip to Lindau in Germany. 

At ANSTO LifeSciences radionuclides are central to nuclear medicine research and to answering fundamental questions in biology. 

Future stars of Australian science, including Campbelltown local Anwen Krause-Heuer, have been handpicked from a global list of thousands to meet with Nobel Prize winners in Germany.

The Australian mango fruit grower’s market is a substantial industry sector that is anticipated to grow by 20% in 2014.The ripening, transportation, and saleable life-span of mangoes depends on keeping the fruit free from pests and disease.

Australian patients will benefit from a new collaboration announced between the ANSTO and US Radiopharmaceuticals (USR).

Nuclear scientists are a step closer to improving the detection of some of the most deadly skin cancers following successful human trials of a novel image tracer for PET scanners.  

The translocator protein is a marker of inflammation in the brain, neuroinflammation, which is implicated in diseases such as multiple sclerosis and Alzheimer’s disease.

The translocator protein is a vital component in stress and anxiety regulation. This study investigates the influence of continuous administration of cannabinoid on the translocator protein in both adult and adolescent rats.

The genetic information of a mammal cell is stored in two types of molecules: deoxyribonucleic acid (DNA) and ribonucleic acid (RNA).

Ever asked yourself why some animals can regenerate lost body parts, yet we can't grow back a limb? A new Australian research collaboration is offering a chance to solve this puzzle in the fight to cure degenerative diseases.

Is understanding the life of cells the key to a cure for cancer? Researchers are suggesting new insights into what makes cells tick, are now leading to potential treatments for cancer.

Research being conducted at ANSTO is helping to refine the radioisotopes that will be used to target tumours in the next generation radiopharmaceuticals for treatment and diagnosis of cancer.

Pharmaceuticals that seek out cancerous cells and deliver treatments to them; imaging techniques that can help doctors detect diseases before the physical signs begin to appear.

University of Sydney and other leading universities in the Asia-Pacific region demonstrates the important role that molecular imaging will play in unravelling the molecular mechanisms of disease.

A medical breakthrough by researchers from ANSTO is backed in a bid to commercialise a way to image and manage patients with Alzheimer’s and Parkinson’s disease by the pharmaceutical company Bayer Schering Pharma.

A major class of brain diseases called ‘synucleinopathies’, is characterised by the abnormal deposition of the protein a-synuclein (a-syn) in nerve cells (neurons). 

Imaging of the living brain using Positron Emission Tomography (PET), a noninvasive, sensitive and quantitative imaging methodology, allows us to investigate neurobiological mechanisms involved in the onset of the neurological disease.

Cannabis use in teenagers can result in the development of drug dependence and has the potential to trigger psychosis and schizophrenia in vulnerable individuals.

Radiation transport simulations were compared with experimental measurements obtained at the High Energy Reference Field facility at CERN.